Report
Olga Smolentseva

INVEST SECURITIES - Quantum Genomics : NEW-HOPE for success in hypertension - ACHAT, OC 9€

Nous ré-initions la couverture de QUANTUM GENOMICS avec une recommandation ACHAT assortie d'un objectif de cours de 9,0€. L'actif le plus avancé de la société, firibastat, a affiché des résultats topline positifs pour son étude de phase IIb chez une population à haut risque d'hypertension. Nous attendons désormais un lancement de phase III en hypertension résistante au S2 19, suivi de la signature potentielle d'un accord de licence. En cas d'issue positive de l'étude de phase III, firibastat pourrait devenir le premier médicament antihypertenseur de sa catégorie pouvant atteindre le marché US et européen en 2023. Selon nous, QUANTUM GENOMICS avec son programme de développement clinique prometteur, est une option attractive pour les investisseurs s'intéressant au marché cardiovasculaire.
Underlying
Quantum Genomics

Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA

Provider
Invest Securities
Invest Securities

Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.

Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.

Analysts
Olga Smolentseva

Other Reports on these Companies
Other Reports from Invest Securities
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli

ResearchPool Subscriptions

Get the most out of your insights

Get in touch